Drugs / recombinant fowlpox-CEA(6D)/TRICOM vaccine
recombinant fowlpox-CEA(6D)/TRICOM vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00091039 | Aug 2004 → Feb 2006 | lung cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant fowlpox-CEA(6D)/TRICOM vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00091039 ↗ |
| Known as | fowlpox-CEA-TRICOM | “Patients receive vaccinia-CEA-TRICOM vaccine subcutaneously (SC) on day 0 and fowlpox-CEA-TRICOM (rF-CEA-TRICOM) vaccine SC on days 14, 29, 43, 57, 70, 91, and 112.” NCT00091039 ↗ |
| Known as | rF-CEA-TRICOM | “Patients receive vaccinia-CEA-TRICOM vaccine subcutaneously (SC) on day 0 and fowlpox-CEA-TRICOM (rF-CEA-TRICOM) vaccine SC on days 14, 29, 43, 57, 70, 91, and 112.” NCT00091039 ↗ |
| Modality | Vaccine | “fowlpox-CEA-TRICOM (rF-CEA-TRICOM) vaccine” NCT00091039 ↗ |
| Route | Subcutaneous | “fowlpox-CEA-TRICOM (rF-CEA-TRICOM) vaccine SC on days 14, 29, 43, 57, 70, 91, and 112” NCT00091039 ↗ |